BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/26/2023 5:44:49 PM | Browse: 283 | Download: 1408
 |
Received |
|
2022-09-06 06:51 |
|
Peer-Review Started |
|
2022-09-06 06:51 |
|
First Decision by Editorial Office Director |
|
2022-10-11 00:49 |
|
Return for Revision |
|
2022-10-11 00:49 |
|
Revised |
|
2022-10-14 11:13 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-12-14 03:21 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-12-15 09:36 |
|
Articles in Press |
|
2022-12-15 09:36 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-12-26 05:52 |
|
Publish the Manuscript Online |
|
2023-01-26 17:44 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Retrospective Study |
| Article Title |
Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yao-Wei Wang, Xin-Hui Wang, Hong-Xia Wang and Ren-Huan Yu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key Research and Development Program of China |
2019YFC1708503 |
|
| Corresponding Author |
Ren-Huan Yu, PhD, Professor, China Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No. 1 Xiyuan Playground, Haidian District, Beijing 100091, China. tezhongeyu@vip.sina.com |
| Key Words |
Refractory nephrotic syndrome; Idiopathic membranous nephropathy; Low-dose rituximab |
| Core Tip |
According to the Kidney Disease Improving Global Outcomes 2021 guidelines, Rituximab (RTX) is now the first-line therapy for patients with idiopathic membranous nephropathy (IMN). However, the use of RTX for the treatment of patients with refractory IMN remains challenging. We conducted a retrospective study on nine patients with refractory phospholipase A2 receptor (PLA2R)-associated MN to explore the efficacy and safety of a new low-dose RTX regimen (RTX, 200 mg, once a month for five months), and conclude that our low-dose RTX regimen is a promising treatment strategy for refractory PLA2R-associated IMN. |
| Publish Date |
2023-01-26 17:44 |
| Citation |
Wang YW, Wang XH, Wang HX, Yu RH. Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience. World J Clin Cases 2022; 11(3): 566-575 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i3/566.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i3.566 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
